The Management of the 2009 pandemic Influenza A H1N1 virus infection
Editorial
The Management of the 2009 pandemic Influenza A H1N1 virus infection
Kelvin K.W. To, Kwok-Yung Yuen
State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
Corresponding to: Kwok-Yung Yuen, MBBS(HK), MD(HK), FRCS(Glas), FRCPath(UK), FRCP(Edin, Lond & Irel), Academician, Chinese Academy of Engineering (Medicine and Health). Carol Yu Centre for Infection and Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, China. Email: kyyuen@hku.hk.
J Thorac Dis 2012;4:4-6. DOI: 10.3978/j.issn.2072-1439.2011.11.01
By far the most important step in the management of a new pandemic viral illness is the availability of a rapid and accurate diagnostic test. Within 1 week of the announcement by the Word Health Organization of the outbreak in Mexico, rapid diagnostic tests based on reverse transcriptase-polymerase chain reaction (RT-PCR) was designed to differentiate this novel influenza A H1N1 virus from the lately circulating seasonal H1N1 and H3N2 virus, and the sporadic avian H5N1 and H9N2 virus (1). This allowed the institution of infection control measures to reduce nosocomial and household transmission. Using the quantitative version of such diagnostic test, the viral load of the respiratory secretions of these infected patients can be measured. Such diagnostic test allowed clinicians to objectively gauge the response to various antiviral or immunomodulating therapy of infected patients. As expected, the early use of oseltamivir therapy can reduce the viral load slightly more rapidly than our immune system with earlier resolution of symptoms (2,3). However we still do not know whether early institution of oseltamivir or other neuraminidase inhibitor can really prevent normal healthy individuals, pregnant women, obese patients and those with chronic underlying illness from progressing to severe illness. The majority of these patients suffered from mild disease and recover without any specific antiviral treatment or with only symptomatic treatment. However some suffered and died from very severe illness with primary viral pneumonia and sometimes secondary bacterial pneumonia which progressed to acute respiratory distress syndrome. These severe cases had delayed viral load clearance with concomitant marked activation of plasma proinflammatory cytokines and chemokines. The mortality is up to 30% even in patients with no underlying illness and despite oseltamivir treatment (4,5). They may have extrapulmonary manifestations such as myocarditis, vascular thrombosis and reactive haemophagocytosis as in the case of avian H5N1 infection. This is not completely unexpected as the new virus is very well adapted to many human cell lines of different organ origins though the lung and intestinal cell lines such as Caco2 appeared better as they can produce endogenous trypsin-like proteases which can enhance proteolytic cleavage of the haemagglutinin for cell entry by membrane fusion (6). Furthermore this new virus can produce a D225G mutant (or D222G with H1 numbering) of haemagglutinin which is associated with severe illness and has a predilection for the α2,3-linked sialic acid receptors more abundantly found in the lower respiratory tract of human (7-10). Interestingly this mutant was also associated with viraemia as demonstrated by RT-PCR (11).
Zhong NS et al. has produced a very comprehensive guideline for the diagnosis and treatment of influenza which can serve Chinese patients who choose to be treated with either Western medicine or traditional Chinese medicine (12). In the former case of antiviral treatment, the adamantanes including the amantadine and rimantadine are not useful for the 2009 pandemic H1N1 virus because of the S31N mutation of the matrix M2 protein. Moreover it has been reported that oseltamivir resistance through the H275Y mutation of the haemagglutinin can emerge in patients without any exposure to oseltamivir as the quasispecies of resistant mutant have the advantage to outgrow sensitive wild type in cell culture (13). It is also important to note that such oseltamivir resistance will result in cross resistance to another neuraminidase inhibitor peramivir. Thus for the treatment of severe cases, other agents such as oro-inhaled or intravenous zanamivir have to be considered. However if the patient has severe pneumonia, inhaled agents will have difficulty of penetrating pulmonary consolidation. The role of sialidase DAS181 is still uncertain. As for polymerase inhibitors such as ribavirin, viramidine and T705, only ribavirin is commercially available but has significant side effects. Though interferons are active in-vitro and in animals, their pro-inflammatory side effects are severe and will not be considered in the clinical setting of severe pneumonia. In fact none of these agents including double-dose oseltamivir has ever been shown to decrease mortality in patients with influenza pneumonia and respiratory failure. Therefore further antiviral targets are being searched such as the nucleozin analogues which aggregate the viral nucleoprotein which is a non-surface and non-enzymatic antiviral target (14). Because elderly patients who have previous exposure to the 1918 pandemic H1N1 virus were relatively protected from the new pandemic 2009 H1N1 virus (15,16), it is conceivable that passive immunotherapy with convalescent plasma or hyperimmune immunoglobulin harvested by plasmapheresis from convalescent patients may be an important treatment option (17,18). Since protective antibody titer is lower after vaccination than natural infection, the convalescent plasma should be collected only from patients with natural infection (19). It is of note that patients with severe disease had a significantly lower serum IgG2 level than those with mild influenza (20). In a case control study, patients with severe influenza pneumonia have a lower mortality, serial viral load and proinflammatory serum cytokine level if treated with convalescent plasma (21). Further randomized control trials should be performed on patients with severe influenza pneumonia to ascertain the role of different treatment options.
References
  • Lau SK, Chan KH, Yip CC, Ng TK, Tsang OT, Woo PC, et al. Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR. J Clin Microbiol 2009;47:2344-6.[LinkOut]
  • To KK, Chan KH, Li IW, Tsang TY, Tse H, Chan JF, et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol 2010;82:1-7.[LinkOut]
  • Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010;137:759-68.[LinkOut]
  • To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010;50:850-9.[LinkOut]
  • Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 2010;201:346-53.[LinkOut]
  • Li IW, Chan KH, To KW, Wong SS, Ho PL, Lau SK, et al. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J Clin Virol 2009;46:325-30.[LinkOut]
  • Chen H, Wen X, To KK, Wang P, Tse H, Chan JF, et al. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis 2010;201:1517-21.[LinkOut]
  • Tse H, Kao RY, Wu WL, Lim WW, Chen H, Yeung MY, et al. Structural basis and sequence co-evolution analysis of the hemagglutinin protein of pandemic influenza A/H1N1 (2009) virus. Exp Biol Med (Maywood) 2011;236:915-25.[LinkOut]
  • Chan KH, Zhang AJ, To KK, Chan CC, Poon VK, Guo K, et al. Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PLoS One 2010;5:e13757.[LinkOut]
  • Zheng B, Chan KH, Zhang AJ, Zhou J, Chan CC, Poon VK, et al. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood) 2010;235:981-8.[LinkOut]
  • Tse H, To KK, Wen X, Chen H, Chan KH, Tsoi HW, et al. Clinical and Virological Factors Associated with Viremia in Pandemic Influenza A/ H1N1/2009 Virus Infection. PLoS One 2011;6:e22534.[LinkOut]
  • Zhong NS, Li YM, Yang ZF, Wang C, Liu YN, Li XW, et al. Chinese guidelines for diagnosis and treatment of influenza (2011). J Thorac Dis 2011;3:274-89.[LinkOut]
  • Chen H, Cheung CL, Tai H, Zhao P, Chan JF, Cheng VC, et al. Oseltamivirresistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970-2.[LinkOut]
  • Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010;28:600-5.[LinkOut]
  • To KK, Wong SS, Li IW, Hung IF, Tse H, Woo PC, et al. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad Med J 2010;86:515- 21.[LinkOut]
  • Zhang AJ, To KK, Tse H, Chan KH, Guo KY, Li C, et al. High incidence of severe influenza among individuals aged over 50 years. Clin Vaccine Immunol 2011;18:1918-24.[LinkOut]
  • Wu JT, Lee CK, Cowling BJ, Yuen KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proc Natl Acad Sci U S A 2010;107:3269-74.[LinkOut]
  • Hung IF, To KK, Lee CK, Lin CK, Chan JF, Tse H, et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010;51:274-9.[LinkOut]
  • Chan KH, To KK, Hung IF, Zhang AJ, Chan JF, Cheng VC, et al. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol 2011;18:867-73.[LinkOut]
  • Chan JF, To KK, Tse H, Lau CC, Li IW, Hung IF, et al. The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. Clin Vaccine Immunol 2011;18:305-10.[LinkOut]
  • Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447-56.[LinkOut]
Cite this article as: To KK, Yuen KY. The management of the 2009 pandemic influenza A H1N1 virus infection. J Thorac Dis 2012;4(1):4-6. doi: 10.3978/j.issn.2072-1439.2011.11.01